logo

Astellas Pharma Inc. (ALPMY)



Trade ALPMY now with
  Date
  Headline
1/20/2023 1:02:56 AM Astellas : FDA Lifts Clinical Hold On FORTIS Trial Of AT845 Investigational Treatment For Late-Onset Pompe Disease
1/19/2023 12:37:58 AM Astellas Pharma Gets SBTi Approval For Revised Science-Based Climate Goals To Reduce Greenhouse Gas Emissions
1/9/2023 7:36:30 AM Selecta Biosciences And Astellas Announce Licensing And Development Agreement For Xork IgG Protease
12/21/2022 8:11:00 PM Astellas, Eisai, Daiichi Sankyo, Takeda To Collaborate To Reduce Environmental Burden In Field Of Pharma Packaging
12/20/2022 6:48:07 AM Astellas : FDA Accepts SBLAs For PADCEV Combination For Treatment Of Metastatic Urothelial Cancer
10/31/2022 2:38:37 AM Astellas Pharma H1 Basic Core EPS 65.78 Yen Vs 53.30 Yen Last Year
10/12/2022 12:15:14 AM Astellas To Present Phase 3 Long-Term Safety Study Data Of Fezolinetant At North American Menopause Society Meeting
9/12/2022 9:02:23 AM Astellas Reports Results Of Trial Of PADCEV -KEYTRUDA &PADCEV As Monotherapy In First-Line Advanced Urothelial Cancer
8/18/2022 2:34:47 AM FDA Accepts Astellas' NDA For Fezolinetant For Treatment Of Vasomotor Symptoms Associated With Menopause